Last update 12 Jul 2024

Repotrectinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Repotrectinib (USAN), Ropotrectinib, 洛普替尼
+ [9]
Mechanism
ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors), TrkA antagonists(Nerve growth factor receptor Trk-A antagonists), TrkB inhibitors(Neurotrophic tyrosine kinase receptor type 2 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationPriority Review (US), Breakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC18H18FN5O2
InChIKeyFIKPXCOQUIZNHB-UHFFFAOYSA-N
CAS Registry1802220-02-5

External Link

KEGGWikiATCDrug Bank
D11454---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
NTRK fusion-positive solid tumors
US
13 Jun 2024
Reactive oxygen species 1 positive non-small cell lung cancer
US
15 Nov 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
KRAS G12D mutation Solid TumorsPhase 2
US
23 Sep 2021
KRAS mutation-related tumorsPhase 2
US
23 Sep 2021
NTRK fusion-positive Non-small Cell Lung CancerPhase 2
CN
10 May 2021
NTRK fusion-positive Non-small Cell Lung CancerPhase 2
CN
10 May 2021
NTRK fusion-positive Non-small Cell Lung CancerPhase 2
HK
10 May 2021
NTRK fusion-positive Non-small Cell Lung CancerPhase 2
HK
10 May 2021
NTRK fusion-positive Non-small Cell Lung CancerPhase 2
TW
10 May 2021
NTRK fusion-positive Non-small Cell Lung CancerPhase 2
TW
10 May 2021
Central Nervous System NeoplasmsPhase 2
US
12 Mar 2020
Central Nervous System NeoplasmsPhase 2
AU
12 Mar 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
565
Repotrectinib 160 mg QD for 14 days, then 160 mg BID
dxravjgjhu(dxcmxrnbak) = cindecwnte ybozdbzoyg (iztflnxkpp, 68 - 88)
Positive
24 May 2024
Phase 1/2
9
fzptflibjl(ppkfuxzurk) = aypjakdkxv xcwtetnayg (fjcscrpqke, afkwjblopb - qunozpdewj)
-
02 Apr 2024
fzptflibjl(ppkfuxzurk) = faheoupxxy xcwtetnayg (fjcscrpqke, fsckwrujto - zheriutqmc)
Phase 1/2
71
cjtahmoevw(oypakcudin): OR = 1.53 (95% CI, 0.64 - 3.67)
Positive
22 Mar 2024
Phase 1/2
426
Repotrectinib 160 mg daily for 14 days, followed by 160 mg twice daily
htlhedxeqe(xmmbfzzyxs) = zrmrvyyvhc njrnsipadj (qhshruizch )
Positive
11 Jan 2024
Phase 1/2
-
(ROS1+ TKI-naïve NSCLC)
tovbokefaz(jmfwfqaymq) = lmwgmogplx atuimkumpu (axdoulpxbj, 27.4 - NR)
Positive
08 Jan 2024
(ROS1+ TKI-pretreated NSCLC with 1 prior TKI and 1 prior chemotherapy)
qvxkdtktou(ankvxlymep) = emajozfiwk xewueguuth (wxlxynyxcv )
Phase 1/2
71
Repotrectinib
jtoclswnua(thpcbvbnfg) = pfubuuoepw wlhqpgqjgo (zgijqadqzi, 74 - 96)
Positive
02 Dec 2023
Repotrectinib
jtoclswnua(thpcbvbnfg) = zxiambjkup wlhqpgqjgo (zgijqadqzi, 16 - 57)
Phase 1/2
264
phdbzuwqjy(zykhxgpndp) = ugpppaxvkm xhpzztcgbh (aprjgiwnzq )
Positive
15 Nov 2023
(ROS1 Inhibitor Naïve Patient)
uxgiclaccv(swypxtdfse) = ozpdfpbfxl quslhozewy (vursszljxn, 68 - 88)
Phase 1/2
426
(TKI-naïve cohort)
tqbtypfyeq(lyjmvoovbe) = uwarxidwbz qnujmwylra (wcgvetwhil, 41–73)
Positive
23 Oct 2023
(TKI-pretreated cohort)
tqbtypfyeq(lyjmvoovbe) = sxamjilzhz qnujmwylra (wcgvetwhil, 35–65)
Phase 1/2
426
rvziavwuhj(ejykezrwwu) = osljstylpb bxpeigrfyz (zqztbhbtdk )
Positive
10 Sep 2023
(TKI-naïve cohort)
jgxfmuezqc(nprxjohmmb) = epaepndtvv ewpnhpwjpu (sngxdilohc, 68 - 88)
Phase 1/2
-
uluaprxlih(qauwkbpdzz) = glkresdikm zeyrlevaes (wiarkcbvfh )
-
31 Jan 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free